Core Viewpoint - The legal opinion letter from Hunan Qiyuan Law Firm confirms that the adjustments to the 2021 and 2024 restricted stock incentive plans of Kewei Medical Technology Co., Ltd. comply with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1][10][13]. Approval and Authorization - The company held its first board meeting on December 5, 2021, where it approved the draft of the 2021 restricted stock incentive plan and related matters [4][5]. - The company convened its second extraordinary general meeting on December 21, 2021, to approve the 2021 restricted stock incentive plan [6]. - On April 24, 2023, the company approved adjustments to the 2021 restricted stock incentive plan during its board and supervisory board meetings [6][7]. - The company held its second board meeting on March 1, 2024, to approve the draft of the 2024 restricted stock incentive plan [8][9]. Adjustment of Related Matters - The company held its 2024 annual general meeting on May 21, 2024, where it approved a cash dividend distribution of 12 yuan per 10 shares, totaling approximately 244 million yuan [10]. - The adjustments to the grant prices of the restricted stocks for both the 2021 and 2024 incentive plans were made in accordance with the provisions regarding capital increases and dividend distributions [11][12]. Conclusion - The legal opinion asserts that the adjustments to the 2021 and 2024 incentive plans are in compliance with the relevant laws and regulations, ensuring the legality and validity of the actions taken by the company [13].
可孚医疗: 湖南启元律师事务所关于可孚医疗科技股份有限公司调整2021年限制性股票激励计划以及2024年限制性股票激励计划相关事项的法律意见书